PBYI:NASDAQPuma Biotechnology Inc Analysis

Puma Biotechnology is trading at $7.23, just above its 20‑day SMA of $7.05 and comfortably above the 200‑day SMA of $6.07, indicating short‑term momentum while still respecting long‑term trend. The MACD histogram has turned positive and the signal line is bullish, with RSI at 54 suggesting the stock is neither overbought nor oversold. Support sits near $6.60 and resistance near $7.45, giving a modest upside window, while 30‑day volatility of over 33% signals a fairly swing‑prone price action. Fundamentally, the PE of 15 is well below the biotech industry average of 24.9 and the DCF fair value of $12.98 points to a substantial valuation gap, classifying the stock as undervalued. Recent earnings showed a narrower loss than expected and revenue of $44.8 M beat estimates, though year‑over‑year sales slipped 2.6%.
However, the company faces high sector and regulatory risk due to its reliance on product approvals and a pipeline still in trial phases, while its geographic exposure is limited to the United States and it carries no dividend obligations.